I, Ms MP MATSOSO, Director-General for Health, have determined in accordance with Regulation 14 (5) of the Regulations Relating to a Transparent Pricing System for Medicines and Scheduled Substances published in Government Gazette number 28214 of 11 November 2005 that information relating to cost-effectiveness of a medicine or scheduled substance relative to that of other medicines or scheduled substances in the same therapeutic class should be compiled in a manner consistent with the guidelines appended to this Notice which shall be reviewed from time to time.